Technology has transformed every aspect of our lives. Yet, it still takes 12 years to develop a single drug because 90% of drugs fail in clinical trials, leaving hundreds of millions of patients without effective treatments. Accelerating the pace of bringing new, effective medicines to patients is one of the greatest opportunities for humanity.
Our mission is to develop better drugs, faster using artificial intelligence (AI) and human data. We have created a proprietary, all-in-human AI drug discovery engine, CONVERGE, which houses one of the field's largest and most comprehensive databases of multi-modal patient data sourced directly from human tissue. We use machine learning to map the complex causes of disease, discover new targets with a greater probability of success, and de-risk drug development.
We have delivered 2 new drugs from CONVERGE to clinical trials, discovered 282 new targets, and signed 2 commercial partnerships with Eli Lilly and AstraZeneca totaling $1.6B. We are a team of engineers, neuroscientists, and drug developers united around an audacious vision: to build the Genentech of the digital age.
Technology has transformed almost every single aspect of our lives. Yet, it still takes 12 years to develop a single drug. Thousands of diseases affecting hundreds of millions of people have no effective treatment. Accelerating the pace of bringing effective, new medicines to patients is one of the greatest opportunities for humanity. The biggest driver of rising drug development timelines today are the high rates of drug failures in clinical trials.
Our mission is to develop better drugs, faster using AI to improve clinical success rates. CONVERGE, our AI drug discovery engine, houses one of the field’s largest proprietary multi-modal human tissue datasets. We use machine learning to map the complex causes of disease, discover new targets with a greater probability of success, and de-risk development decisions.
We have delivered 2 new targets from data to clinical drugs, discovered 282 new targets, and signed 2 commercial partnerships with Eli Lilly and AstraZeneca totalling $1.6B. We have raised $180M from top tier investors (e.g. BlackRock, Eli Lilly, Merck, Section 32, Threshold Ventures, Y Combinator, etc.). We are a team of engineers, neuroscientists, and drug developers united around an audacious vision: to build the next Genentech of the digital age.
We are looking for a 0-to-1 technical product leader to drive the evolution of CONVERGE, our AI-powered discovery engine, into new revenue-generating product lines and transform how biotech leverages human data.
Finally, we seek candidates who embrace our values and way of working: